Found: 13
Select item for more details and to access through your institution.
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 172, doi. 10.1007/s10637-019-00801-8
- By:
- Publication type:
- Article
Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2022, v. 52, n. 12, p. 1060, doi. 10.1111/hepr.13827
- By:
- Publication type:
- Article
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
- By:
- Publication type:
- Article
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
- By:
- Publication type:
- Article
Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 5, p. 596, doi. 10.1159/000508809
- By:
- Publication type:
- Article
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 4, p. 382, doi. 10.1159/000507022
- By:
- Publication type:
- Article
Switching to systemic therapy after locoregional treatment failure: Definition and best timing.
- Published in:
- Clinical & Molecular Hepatology, 2020, v. 26, n. 2, p. 155, doi. 10.3350/cmh.2019.0021n
- By:
- Publication type:
- Article
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84117-9
- By:
- Publication type:
- Article
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 4, p. 590, doi. 10.1002/cncr.34559
- By:
- Publication type:
- Article
Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma.
- Published in:
- JGH Open, 2021, v. 5, n. 2, p. 273, doi. 10.1002/jgh3.12483
- By:
- Publication type:
- Article
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
- Published in:
- BMC Gastroenterology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12876-023-02731-5
- By:
- Publication type:
- Article
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
- Published in:
- BMC Gastroenterology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12876-023-02674-x
- By:
- Publication type:
- Article